Puma Biotechnology Inc. PBYI nearly tripled in value Wednesday on positive trial data for its lead breast cancer drug while an analyst said the company is a likely takeover target.
After the close Tuesday, the company said a Phase III clinical trial of its neratinib breast cancer drug found it increased disease-free survival by 33 percent. It plans to seek U.S. marketing clearance in the first half of 2015.
"With patent protection until 2030, we see Puma as a likely takeover candidate," Citi Research's Yaron Werber said in a note.
Werber said his discounted cash flow analysis suggests a takeover bid of $291 to
$351 a share. He rates the stock a Buy with a target of $292.
UBS' Matthew Roden said results from the trial suggest the drug's potential is "much larger than we had previously modeled."
Roden maintained a Buy rating and raised his target 160 percent to $325, from $125, noting that neratinib has potential for treating additional forms of cancer.
Puma traded recently at $217.97 up nearly 270 percent. Shares closed Tuesday at just below $60.
Read more: http://www.nasdaq.com/article/puma-biotechnology-inc-pbyi-has-soared-to-a-new-high-on-phase-3-data-20140723-00579#ixzz38IlQEc7F
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in